1. Tryptophan 2, 3‑dioxygenase promotes proliferation, migration and invasion of ovarian cancer cells
- Author
-
Qin He, Xiaoxiao Cheng, Kai-Fu Tang, Rongying Ou, Yunsheng Xu, Jiayu Jiang, Lina Chen, Yuemei Zhao, Shouhui Zhong, Jizao Du, Xiaoli Wu, Fengxing Tao, and Wei Chen
- Subjects
0301 basic medicine ,Cancer Research ,Carcinogenesis ,proliferation ,Cell ,tryptophan 2,3-dioxygenase ,Carcinoma, Ovarian Epithelial ,Biology ,migration ,Biochemistry ,03 medical and health sciences ,0302 clinical medicine ,Cell Movement ,Cell Line, Tumor ,Genetics ,medicine ,Humans ,Molecular Biology ,Kynurenine ,Cell Proliferation ,Ovarian Neoplasms ,Gene knockdown ,Oncogene ,Cell growth ,Cancer ,Articles ,Cell cycle ,invasion ,medicine.disease ,Molecular medicine ,Tryptophan Oxygenase ,Up-Regulation ,Gene Expression Regulation, Neoplastic ,ovarian cancer ,Cell Transformation, Neoplastic ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Cancer research ,Molecular Medicine ,Female ,Ovarian cancer - Abstract
Tryptophan 2,3‑dioxygenase (TDO2) is a key rate‑limiting enzyme in the kynurenine pathway and promotes tumor growth and escape from immune surveillance in different types of cancer. The present study aimed to investigate whether TDO2 serves a role in the development of ovarian cancer. Reverse transcription‑quantitative PCR and western blotting were used to detect the expression of TDO2 in different cell lines. The effects of TDO2 overexpression, TDO2 knockdown and TDO2 inhibitor on ovarian cancer cell proliferation, migration and invasion were determined by MTS, colony formation and Transwell assays. The expression of TDO2 in ovarian cancer tissues, normal ovarian tissues and fallopian tube tissues were analyzed using the gene expression data from The Cancer Genome Atlas and Genotype‑Tissue Expression project. Immune cell infiltration in cancer tissues was evaluated using the single sample gene set enrichment analysis algorithm. The present study found that RasV12‑mediated oncogenic transformation was accompanied by the upregulation of TDO2. In addition, it was demonstrated that TDO2 was upregulated in ovarian cancer tissues compared with normal ovarian tissues. TDO2 overexpression promoted proliferation, migration and invasion of ovarian cancer cells, whereas TDO2 knockdown repressed these phenotypes. Treatment with LM10, a TDO2 inhibitor, also repressed the proliferation, migration and invasion of ovarian cancer cells. The present study indicated that TDO2 can be used as a new target for the treatment of ovarian cancer.
- Published
- 2021